{
  "id": "606b767294d57fd87900006d",
  "type": "list",
  "question": "Which recombinant antibody therapeutics were granted marketing approval in 2014?",
  "ideal_answer": "Six recombinant antibody therapeutics (vedolizumab, siltuximab, ramucirumab, pembrolizumab, nivolumab, blinatumomab) were granted their first marketing approvals in 2014.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25484055"
  ],
  "snippets": [
    {
      "text": "The commercial pipeline of recombinant antibody therapeutics is robust and dynamic. As of early December 2014, a total of 6 such products (vedolizumab, siltuximab, ramucirumab, pembrolizumab, nivolumab, blinatumomab) were granted first marketing approvals in 2014. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25484055",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "vedolizumab, siltuximab, ramucirumab, pembrolizumab, nivolumab, blinatumomab"
}